One of the hot new cancer immunotherapy drugs, Merck & Co's Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to 3 studies presented at the American Association for Cancer Research conference.
One of the hot new cancer immunotherapy drugs, Merck & Co's Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to 3 studies presented Sunday at the American Association for Cancer Research conference in Philadelphia.
One study, comparing Keytruda to Bristol-Myers Squibb Co's Yervoy, could give Merck a temporary advantage as the rivals battle for market supremacy and billions of dollars in annual sales from this new generation of drugs, which help the immune system destroy cancer cells. While research continues, the pace is quickening and big improvements in patient care regimens are likely fairly soon.
Read more from the Associated Press and ABC News: http://abcn.ws/1D8z4z3
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More